share_log

Eli Lilly and Co | 8-K: Chief Financial Officer Anat Ashkenazi Resigns

Eli Lilly and Co | 8-K: Chief Financial Officer Anat Ashkenazi Resigns

禮來 | 8-K：首席財務官Anat Ashkenazi辭職
美股sec公告 ·  06/05 07:51
Moomoo AI 已提取核心訊息
Eli Lilly and Company, a leading pharmaceutical firm, announced on June 5, 2024, that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to pursue a new career opportunity outside of the pharmaceutical industry. Ashkenazi, who has been with Eli Lilly for 23 years, will continue her duties and remain a member of the Executive Committee until July 2024. During her tenure as CFO, the company experienced significant growth and established a foundation for future success. Prior to her role as CFO, Ashkenazi held various financial leadership positions within the company, including senior vice president and controller of Lilly Research Laboratories. Eli Lilly has commenced both internal and external searches to find Ashkenazi's successor. The announcement was made through a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
Eli Lilly and Company, a leading pharmaceutical firm, announced on June 5, 2024, that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to pursue a new career opportunity outside of the pharmaceutical industry. Ashkenazi, who has been with Eli Lilly for 23 years, will continue her duties and remain a member of the Executive Committee until July 2024. During her tenure as CFO, the company experienced significant growth and established a foundation for future success. Prior to her role as CFO, Ashkenazi held various financial leadership positions within the company, including senior vice president and controller of Lilly Research Laboratories. Eli Lilly has commenced both internal and external searches to find Ashkenazi's successor. The announcement was made through a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
領先藥品公司艾麗莎於2024年6月5日宣佈，Anat Ashkenazi已辭去其首席財務官(CFO)的職位，並為了開展藥品行業之外的新職業機會。在Eli Lilly的23年任期中，Ashkenazi將繼續履行職責，並成為執行委員會成員直到2024年7月。在擔任CFO期間，公司業務成長顯著，為未來的成功打下了基礎。在擔任CFO之前，Ashkenazi還擔任該公司的各種財務領導職務，包括Lilly Research Laboratories的高級副總裁和控制器。Eli Lilly已經開始進行內部和外部搜索，以尋找Ashkenazi的繼任者。此公告通過附件為Exhibit 99.1的新聞稿公佈，該公司的8-K表格已經向SEC提交。
領先藥品公司艾麗莎於2024年6月5日宣佈，Anat Ashkenazi已辭去其首席財務官(CFO)的職位，並為了開展藥品行業之外的新職業機會。在Eli Lilly的23年任期中，Ashkenazi將繼續履行職責，並成為執行委員會成員直到2024年7月。在擔任CFO期間，公司業務成長顯著，為未來的成功打下了基礎。在擔任CFO之前，Ashkenazi還擔任該公司的各種財務領導職務，包括Lilly Research Laboratories的高級副總裁和控制器。Eli Lilly已經開始進行內部和外部搜索，以尋找Ashkenazi的繼任者。此公告通過附件為Exhibit 99.1的新聞稿公佈，該公司的8-K表格已經向SEC提交。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息